Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non Operating Income: 2020-2024

Historic Other Non Operating Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$23.5 million.

  • Xeris Biopharma Holdings' Other Non Operating Income rose 0.96% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 24.40%. This contributed to the annual value of -$23.5 million for FY2024, which is 20.33% down from last year.
  • As of FY2024, Xeris Biopharma Holdings' Other Non Operating Income stood at -$23.5 million, which was down 20.33% from -$19.5 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Non Operating Income peaked at -$7.6 million during FY2021, and registered a low of -$23.5 million during FY2024.
  • In the last 3 years, Xeris Biopharma Holdings' Other Non Operating Income had a median value of -$19.5 million in 2023 and averaged -$19.0 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Other Non Operating Income climbed by 1.75% in 2021 and then tumbled by 86.87% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Non Operating Income (Yearly) stood at -$7.7 million in 2020, then increased by 1.75% to -$7.6 million in 2021, then plummeted by 86.87% to -$14.1 million in 2022, then slumped by 37.83% to -$19.5 million in 2023, then dropped by 20.33% to -$23.5 million in 2024.